Tilray Medical has given an update on its operations in Italy, with the launch of Tilray Medical Italia, the new name of the entity previously known as FL Group.
Rajnish Ohri, President International at Tilray Brands, stated, "Italy remains a strategically important market for Tilray Medical as we continue to build a leading, regulated medical cannabis platform across Europe. The launch of Tilray Medical Italia strengthens our local presence, aligns our operations under a single global medical brand, and reinforces our long-term commitment to supporting patients, physicians, and healthcare systems with high-quality, authorized medical cannabis products."
© Tilray Brands
Tilray Medical Italia operates within Italy's established medical cannabis framework, supplying products authorized by the Ministry of Health and distributed through hospital and pharmacy channels in accordance with national regulations. The Company's Italian operations are supported by Tilray's broader European medical infrastructure, including pharmaceutical-grade cultivation, manufacturing, quality assurance, and regulatory expertise developed across multiple federally legal medical cannabis markets.
Through its partnership with Molteni, Tilray Medical Italia continues to support physician education, responsible prescribing, and patient access, while maintaining rigorous standards for product quality, safety, and compliance.
Mr. Ohri continued, "Our collaboration with Molteni enables us to effectively serve the Italian medical community while maintaining the highest standards expected in a regulated pharmaceutical environment. As demand for medical cannabis continues to evolve, Tilray Medical Italia is well positioned to responsibly support the market's development."
For more information:
Tilray
www.tilray.com
